Related Experiment Videos
Clinical comparison of metrizamide and iopamidol for myelography
AJNR. American Journal of Neuroradiology
|May 1, 1983
Abstract:
A double-blind parallel comparison of iopamidol and metrizamide for myelography was performed in 36 patients. Sixteen adverse reactions were noted in 10 patients who received metrizamide. Six adverse reactions were reported in five patients who received iopamidol. There was no appreciable difference in the radiographic opacification.
Insights
Iopamidol showed fewer adverse reactions than metrizamide during myelography, with similar radiographic quality. This suggests iopamidol may be a safer contrast agent for spinal imaging.
Area of Science:
- Radiology
- Neuroradiology
- Medical Imaging
Background:
- Myelography is a diagnostic imaging procedure.
- Contrast agents are essential for visualizing the spinal canal.
- Evaluating the safety and efficacy of different contrast agents is crucial.
Purpose of the Study:
- To compare the safety and efficacy of iopamidol and metrizamide for myelography.
- To assess adverse reactions associated with each contrast agent.
- To evaluate radiographic opacification differences between iopamidol and metrizamide.
Main Methods:
- A double-blind, parallel comparison study.
- Involved 36 patients undergoing myelography.
- Iopamidol and metrizamide were administered and compared.
Main Results:
- Iopamidol group: 6 adverse reactions in 5 patients.
- Metrizamide group: 16 adverse reactions in 10 patients.
- No significant difference in radiographic opacification between agents.
Conclusions:
- Iopamidol demonstrated a lower incidence of adverse reactions compared to metrizamide.
- Both agents provided comparable radiographic opacification for myelography.
- Iopamidol may be a preferred contrast agent due to its improved safety profile.